The therapeutic efficacy of the c-Met inhibitor savolitinib was evaluated in a mouse model of arthritis.<h4>Results</h4>Plasma HGF levels were significantly elevated in RA patients (<i>p</i> = 0.0003) and correlated with Disease Activity Score 28-ESR (r = 0.367, <i>p</i> = 0.002). This evidence concerns the gene MET and arthritic joint disease.